JOURNAL ARTICLE

Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.

  • Published In: British Journal of Dermatology, 2024, v. 190, n. 5. P. 729 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Mukhtar, Abdullahi B; Morgan, Huw J; Gibbs, Alex; Davies, Gemma E; Lovatt, Charlotte; Patel, Girish K 3 of 3

Abstract

This article focuses on identifying a subpopulation of malignant melanoma (MM) cells intrinsically resistant to BRAF-targeted therapies, which may contribute to disease recurrence. Using three-dimensional nonadherent culture conditions, the study established reproducible melanosphere formation from MM cell lines and identified a CD20-positive (CD20⁺) MM cell subpopulation that persists despite BRAF inhibitor treatment. RNA sequencing revealed that CD20⁺ cells exhibit distinct transcriptional profiles associated with resistance, including activation of Forkhead box protein M1 (FOXM1). Combining BRAF inhibitors with anti-CD20 antibody therapy (rituximab) enhanced killing of these resistant cells in vitro, suggesting a potential therapeutic strategy to prevent MM recurrence in patients harboring CD20⁺ subpopulations.

Additional Information

  • Source:British Journal of Dermatology. 2024/05, Vol. 190, Issue 5, p729
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2024
  • ISSN:0007-0963
  • DOI:10.1093/bjd/ljad502
  • Accession Number:176761076
  • Copyright Statement:Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.